Evolving end points for clinical trials in advanced colorectal cancer

Sharlene Gill, Daniel J. Sargent

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The treatment of advanced colorectal cancer has evolved significantly over recent years. The increasing and justified demand for timely and robust evaluation of emerging therapies has led to the careful evaluation of alternative end points for clinical trials beyond overall survival. This review offers insights into the advantages, limitations, and promise of existing and emerging efficacy end points of interest for advanced colorectal cancer.

Original languageEnglish (US)
Pages (from-to)135-139
Number of pages5
JournalCurrent Colorectal Cancer Reports
Volume5
Issue number3
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Evolving end points for clinical trials in advanced colorectal cancer. / Gill, Sharlene; Sargent, Daniel J.

In: Current Colorectal Cancer Reports, Vol. 5, No. 3, 07.2009, p. 135-139.

Research output: Contribution to journalArticle

Gill, Sharlene ; Sargent, Daniel J. / Evolving end points for clinical trials in advanced colorectal cancer. In: Current Colorectal Cancer Reports. 2009 ; Vol. 5, No. 3. pp. 135-139.
@article{1401057cf2e34de0845dabf393dc0e4d,
title = "Evolving end points for clinical trials in advanced colorectal cancer",
abstract = "The treatment of advanced colorectal cancer has evolved significantly over recent years. The increasing and justified demand for timely and robust evaluation of emerging therapies has led to the careful evaluation of alternative end points for clinical trials beyond overall survival. This review offers insights into the advantages, limitations, and promise of existing and emerging efficacy end points of interest for advanced colorectal cancer.",
author = "Sharlene Gill and Sargent, {Daniel J.}",
year = "2009",
month = "7",
doi = "10.1007/s11888-009-0020-y",
language = "English (US)",
volume = "5",
pages = "135--139",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Evolving end points for clinical trials in advanced colorectal cancer

AU - Gill, Sharlene

AU - Sargent, Daniel J.

PY - 2009/7

Y1 - 2009/7

N2 - The treatment of advanced colorectal cancer has evolved significantly over recent years. The increasing and justified demand for timely and robust evaluation of emerging therapies has led to the careful evaluation of alternative end points for clinical trials beyond overall survival. This review offers insights into the advantages, limitations, and promise of existing and emerging efficacy end points of interest for advanced colorectal cancer.

AB - The treatment of advanced colorectal cancer has evolved significantly over recent years. The increasing and justified demand for timely and robust evaluation of emerging therapies has led to the careful evaluation of alternative end points for clinical trials beyond overall survival. This review offers insights into the advantages, limitations, and promise of existing and emerging efficacy end points of interest for advanced colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=79952693213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952693213&partnerID=8YFLogxK

U2 - 10.1007/s11888-009-0020-y

DO - 10.1007/s11888-009-0020-y

M3 - Article

AN - SCOPUS:79952693213

VL - 5

SP - 135

EP - 139

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -